What is claimed:

1. A compound comprising a modified oligonucleotide consisting of less than 16 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide comprises a nucleobase sequence that is complementary to nucleobases 2 to 9 of miR-122 (SEQ ID NO: 1), and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following structure:

   $A_E{}^{Me}C_EA_E{}^{Me}C_E{}^{Me}C_EA_ET_ETGU_SC_SAC_SAC_STC_SC_S$ (SEQ ID NO: 4),


   wherein the superscript "Me" indicates 5-methylcytosine, wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, nucleosides followed by a subscript "S" are S-cEt nucleosides, and each internucleoside linkage is a phosphorothioate internucleoside linkage.

2. The compound of claim 1, wherein the compound comprises a conjugate moiety linked to the 5' terminus or the 3' terminus of the modified oligonucleotide.

3. The compound of claim 2, wherein the compound has the structure:
   L_n-linker-X_1-N_m-X_2-MO

wherein each L is, independently, a ligand and n is 3; each N is, independently, a modified or unmodified nucleoside and m is from 1 to 5; X_1 and X_2 are each, independently, a phosphodiester linkage or a phosphorothioate linkage; and MO is the modified oligonucleotide.

4. The compound of claim 3, wherein the compound has the structure:



wherein:

B is selected from –O-, -S-, -N(R^N)-, –Z-P(Z')(Z")O-, –Z-P(Z')(Z")O-N_m-X-, and –Z-P(Z')(Z")O-N_m-Y-;

MO is the modified oligonucleotide;

R^N is selected from H, methyl, ethyl, propyl, isopropyl, butyl, and benzyl;

Z, Z', and Z" are each independently selected from O and S;

each N is, independently, a modified or unmodified nucleoside;

m is from 1 to 5;


X is selected from a phosphodiester linkage and a phosphorothioate linkage;

Y is a phosphodiester linkage;

each ligand is N-acetylgalactosamine; and

the wavy line indicates the connection to the rest of the linker and ligand(s).

5. The compound of claim 3 or claim 4, wherein the compound has the structure:




wherein each N of N_m is, independently, a modified or unmodified nucleoside and m is from 1 to 5; X_1 and X_2 are each, independently, a phosphodiester linkage or a phosphorothioate linkage; and MO is the modified oligonucleotide.

6. The compound of claim 5, wherein each of X_1 and X_2 is a phosphodiester linkage.

7. The compound of any one of claims 3 to 6, wherein m is 1.

8. The compound of any one of claims 4 to 7, wherein each N comprises an unmodified sugar moiety, wherein each unmodified sugar moiety is, independently, a β-D-ribose or a β-D-deoxyribose.

9. A compound of the structure:



wherein X is a phosphodiester linkage; m is 1; N of N_m is a β-D-deoxyriboadenosine; Y is a phosphodiester linkage; and MO is a modified oligonucleotide consisting of less than 16 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide comprises a nucleobase sequence that is complementary to nucleobases 2 to 9 of miR-122 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the structure $A_E{}^{Me}C_EA_E{}^{Me}C_E{}^{Me}C_EA_ET_ETGU_SC_SAC_SAC_STC_SC_S$ (SEQ ID NO: 4), wherein the superscript "Me" indicates 5-methylcytosine, wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, nucleosides followed by a subscript "S" are S-cEt nucleosides, and each internucleoside linkage is a phosphorothioate internucleoside linkage; and wherein Y is linked to the 3' terminus of the modified oligonucleotide.

10. A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, which is a sterile aqueous solution.

12. Use of the compound of claim 9, or the pharmaceutical composition of claim 10 or claim 11, in the manufacture of a medicament for treating a hepatitis C virus (HCV)-infected human subject.

13. The use of claim 12 wherein the medicament reduces the symptoms of HCV infection, prevents a rebound in serum HCV RNA, and/or delays a rebound in serum HCV RNA.

14. The use of claim 12 or claim 13, wherein the medicament reduces HCV RNA level.

15. The use of any one of claims 12 to 14, wherein the use achieves a sustained virological response.

16. The use of any one of claims 12 to 15, wherein the subject is infected with one or more HCV genotypes selected from genotype 1, genotype 2, genotype 3, genotype 4, genotype 5, and genotype 6.

17. The use of claim 16, wherein the HCV genotype is selected from genotype 1a, genotype 1b, genotype 2a, genotype 2b, genotype 2c, genotype 2d, genotype 3a, genotype 3b, genotype 3c, genotype 3d, genotype 3e, genotype 3f, genotype 4a, genotype 4b, genotype 4c, genotype 4d, genotype 4e, genotype 4f, genotype 4g, genotype 4h, genotype 4i, genotype 4j, genotype 5a, and genotype 6a.

18. The use of any one of claims 12 to 17, wherein the medicament is to be administered in combination with at least one additional therapeutic agent.

19. The use of claim 18, wherein the at least one therapeutic agent is selected from a protease inhibitor, a polymerase inhibitor, a cofactor inhibitor, an RNA polymerase inhibitor, a structural protein inhibitor, a non-structural protein inhibitor, a cyclophilin inhibitor, an entry inhibitor, a TLR7 agonist, an NS5A inhibitor, an NS3/4A inhibitor, a nucleoside NS5B inhibitor, a nucleotide NS5B inhibitor, a non-nucleoside NS5B inhibitor, and an interferon.

20. The use of claim 18, wherein the at least one therapeutic agent is selected from interferon alfa-2a, interferon alpha-2b, interferon alfacon-1, peginterferon alpha-2b, peginterferon alpha-2a, interferon-alpha-2b extended release, interferon lambda, sofosbuvir, ledipasvir, ribavirin, telapravir, boceprevir, vaniprevir, asunaprevir, ritonavir, setrobuvir, daclastavir, simeprevir, alisporivir, mericitabine, tegobuvir, danoprevir, sovaprevir, and neceprevir.

21. The use of claim 20, wherein the at least one therapeutic agent is sofosbuvir.

22. The use of claim 20, wherein the at least one therapeutic agent is sofosbuvir and ledipasvir.

23. The use of claim 20, wherein the at least one therapeutic agent is daclatasvir.

24. The use of claim 20, wherein the at least one therapeutic agent is simeprevir.

25. The use of any one of claims 12 to 24, wherein the subject is a direct-acting anti-viral non-responder.

26. The use of any one of claims 12 to 25, wherein the subject has an HCV-associated disease, wherein the HCV-associated disease is optionally selected from cirrhosis, liver fibrosis, steatohepatitis, steatosis, and hepatocellular carcinoma.

27. The use of any one of claims 12 to 26, wherein the compound or pharmaceutical composition is to be administered once per week, once per two weeks, once per three weeks, once per month, once per two months, or once per three months.

28. The use of any one of claims 12 to 27, wherein the dose of the compound or conjugate is less than or equal to 10 mg/kg, less than or equal to 7.5 mg/kg, less than or equal to 5 mg/kg per week, less than or equal to 4.5 mg/kg, less than or equal to 4.0 mg/kg, less than or equal to 3.5 mg/kg, less than or equal to 3.0 mg/kg, less than or equal to 2.5 mg/kg, less than or equal to 2.0 mg/kg, less than or equal to 1.5 mg/kg, or less than or equal to 1.0 mg/kg.